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ABSTRACT
A 15-year-old Iraqi male patient with acute lymphoblastic 
leukemia received an allogeneic bone marrow transplant from his 
brother. On the 18th day  after the transplant, the patient developed 
grade II acute graft-versus-host disease, and treatment included 
methylprednisolone. On day 140, the patient was diagnosed with 
leukoderma. On day 150, the patient was admitted to hospital 
because of numbness and muscle weakness in the extremities and 
a disturbance of the gait. Neurologic examination showed muscle 
weakness in the upper and lower extremities and there were no 
deep tendon reflexes.  Nerve conduction studies showed reduced 
conduction speeds of the motor nerves  with demyelinating 
features.  The patient was diagnosed as having a  chronic 
inflammatory demyelinating polyradiculoneuropathy (CIDB) 
based on clinical and electrophysiological findings. Treatment 
included methylprednisolone and intravenous immunoglobulin. 
The neurologic function improved but the skin lesions persisted. 
This case shows that graft-versus-host disease can act as a triggering 
factor for the appearance of autoimmune diseases. 
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ÖZET
Akut lenfoblastik lösemisi olan 15 yaşındaki Iraklı erkek hastaya 
ağabeyinden allojenik kemik iliği nakli yapıldı. Nakilden 18 gün 
sonra hastada evre 2 graft-versus-host hastalığı gelişti ve tedavi 
olarak metilprednizolon verildi. 140. günde hastaya lökoderma 
tanısı konuldu. 150. günde hasta ekstremitelerde uyuşma, kas 
güçsüzlüğü ve denge bozukluğu nedeniyle başvurdu. Nörolojik 
muayenede üst ve alt ekstremitelerde kas zayıflığı görüldü ve tüm 
derin tendon refleksleri yoktu. Sinir iletim testleri gecikmiş motor 
sinir iletimini gösterdi. Hastaya kronik inflamatuar demiyelinizan 
poliradikülonöropati tanısı klinik ve elektrofizyolojik bulgulara 
dayanılarak konuldu. Tedavi olarak metilprednizolon ve intravenöz 
immunglobulin verildi. Nörolojik fonksiyonları düzeldi fakat 
cilt bulguları devam etti. Bu vaka graft-versus-host hastalığının 
otoimmun hastalıkların ortaya çıkması için tetikleyici bir faktör 
olabileceğini göstermektedir. 
Anahtar kelimeler: Lösemi, Graft-versus-host hastalığı, 
Lökoderma,  Kronik inflamatuar demiyelinizan poliradikülonöropati
Introduction
Chronic graft-versus-host disease (GVHD) is a systemic 
multiorgan syndrome that occurs in 25% to 50% of long 
term hematopoietic cell transplant survivors. Risk factors 
for chronic GVHD include previous acute GVHD, older 
patient ages, the use of female donors for male recipients, 
donor lymphocyte infusions, unrelated or human leukocyte 
antigen-mismatched donors, and the peripheral blood as a 
source of stem cells [1,2]. GVHD can also occur after a blood 
transfusion if the blood used has not been irradiated [3].
The presentation of chronic GVHD may be progressive, 
quiescent, or de novo late onset. Skin is the most commonly 
affected organ in chronic GVHD, and diagnostic skin 
manifestations of GVHD include poikiloderma, lichen 
planus-like eruptions, lichen sclerosus-like lesions, morphea-
like sclerosis, and deep sclerosis and fasciitis.  Vitiligo is 
not a common complication of GVHD. Additional sites of 
involvement of GVHD include the mouth, eyes, liver, lungs, 
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bone marrow, and vulvovaginal region, and manifestations 
may include esophagal webs and strictures, myositis, 
nephrotic syndrome, pericarditis, peripheral neuropathy, 
and myasthenia gravis [4]. 
We treated an adolescent male patient who had 
Philadelphia chromosome-positive acute lymphoblastic 
leukemia. After an allogeneic stem cell transplant, 
he developed leukoderma and chronic inflammatory 
demyelinating polyradiculoneuropathy (CIDP).
Case Report
A 15-year-old Iraqi male patient in the first remission of 
Philadelphia chromosome-positive acute lymphoblastic 
leukemia received an  allogeneic bone marrow transplant 
from a human leukocyte antigen-matched sibling donor, 
his brother. The patient and brother had no history of 
depigmentary dermatoses. The conditioning regimen 
included busulfan and cyclophosphamide, and cyclosporine 
A was used as prophylaxis against GVHD. 
On day 18 after the transplant, the patient developed 
grade II acute GVHD with skin involvement. The patient 
complained of skin rashes and dryness. Methylprednisolone 
(2 mg/kg/d) was added, tapered after control of the GVHD, 
and stopped on day 41. His symptoms and signs disappeared 
by this therapy. On day 100, he developed renal tubular 
dysfunction related to cyclosporine A; the cyclosporine A 
was stopped and mycophenolate mofetil was started. 
On day 140, the patient began to develop depigmented 
patches on the face, chest, trunk, and extremities. He was 
diagnosed with leukoderma (Figures 1a, b). He was given 
tacrolimus 0.1% and triamcinolone  ointment to apply on 
the affected areas twice daily.  On day 150,  the patient was 
admitted to hospital because of a two day history of sensory 
disturbaces, gait disturbance and muscle weakness in both 
lower and upper extremities. Neurologic examination 
showed muscle weakness in the upper extremties (strength, 
3/6) and lower extremities (strength, 2/6). There were no 
deep tendon reflexes. Autonomic nervous system, cranial 
nerve, and respiratory functions were normal. Cranial 
and spinal cord magnetic resonance imaging scans were 
normal. The cerebrospinal fluid had a protein level 27.8 mg/
dL and contained no cells. There were oligoclonal bands 
detected in the cerebrospinal fluid or serum. Laboratory 
evaluation was negative for human immunodeficiency virus, 
cytomegalovirus, syphilis, viral hepatitis, and autoimmune 
disorders. Nerve conduction studies revealed a slow motor 
nerve  conduction velocity with a low compound muscle 
action potential amplitude in the upper and lower extremities. 
Figure a,b: A-15-year-old male who had Philadelphia 
chromosome-positive acute lymphoblastic leukemia, developed 
leukoderma after an allogeneic bone marrow transplant. The (a) 
chest and (b) back had multiple white, depigmented, sharply-
defined skin lesions consistent with leukoderma. 
The patient was diagnosed with CIDB based on 
clinical and electrophysiological findings.  Treatment 
included methylprednisolone (1 mg/kg/d intravenous) 
and intravenous immunoglobulin (400 mg/kg/d for 5 d). 
Mycophenolate mofetil was continued and sirolimus was 
started. Within 6 weeks after beginning this therapy, there 
was improvement of the muscle weakness(upper extremities 
6/6, lower extremities 5/6) and gait, and the deep tendon 
reflexes became normal.  In spite of topical steroids and 
topical tacrolimus, the patient had persistent areas of 
depigmentation on the face, chest, trunk, and extremities. 
Psoralen and ultraviolet A treatment were not given to the 
patient because of his compromised health status. During 
three months of the follow-up period, depigmentation did 
not spread.
a.
b.
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Discussion
The present patient had a clinical presentation consistent 
with progressive GVHD, with gradual progression 
from acute to chronic GVHD. This was complicated by 
leukoderma and chronic inflammatory demyelinating 
polyradiculoneuropathy.
The present patient had the clinical appearance of 
generalized leukoderma. Neither the patient nor the donor 
had a history of depigmentary dermatoses. Treatment with 
cyclosporine A for GVHD prophylaxis may  have delayed 
the onset of leukoderma in the patient. The GVHD may 
trigger autoimmune diseases in patients who have a genetic 
predisposition to autoimmune disorders. Patients with 
GVHD have a high incidence of detectable autoantibodies 
(including antinuclear, double-stranded DNA  and smooth-
muscle antibodies) and disease-related gene polymorphisms 
common to patients with autoimmune disorders [5].
Pathogenesis of developing vitiligo in GVHD is due to 
increased TNF-α production [6]. Elevated levels of TNF–α 
and IL-6 have been found in vitiligous skin compared to 
adjacent uninvolved skin. It has been suggested that chronic 
GVHD  may be induced by synergistic interaction of IL-6 
and TNF-α [7]. Leukoderma associated with GVHD usually 
shows limited clinical improvement. Tan et al. reported a 
case of stable leucoderma associated with chronic graft-
versus-host disease that achieved repigmentation following 
autologous noncultured cellular transplantation [8].
CIDP is a chronic, acquired, immune mediated 
condition affecting the peripheral nerves. The diagnosis 
of this neuropathy can be established by clinical and 
electromyographic criteria. Nerve biopsy is less often 
required [9]. It is an important complication, and 0.6% 
to 4% patients develop peripheral neuropathy after an 
allogeneic stem cell transplant [10,11].  The pathogenesis of 
CIDP associated with GVHD may include the development 
of nerve demyelination and inflammation secondary to 
immune-mediated effects. This may include cell and 
antibody mediated immune responses to glycolipid or 
myelin protein antigens. 
CIDP typically has an onset of > 90 days after allogeneic 
stem cell transplant. Clinical and neurophysiological findings 
can be the same for CIDP and  Guillian-Barre syndrome 
(GBS).  CIDP symptoms tend to come on more slowly and 
progress for a longer period of time. The distinction between 
CDIB and GBS is also based on the time to maximal 
neurological deficit. For GBS this is 4 weeks and more than 8 
weeks is classifed as CIDB[12]. This polyradiculoneuropathy 
may have a progressive course, with poor response to 
medical treatment. Improvement may occur in 50% to 80% 
patients, usually within a few weeks of treatment. In the 
present patient, the polyradiculoneuropathy was controlled 
with methylprednisolone, intravenous immunoglobulin 
for 5 days, mycophenolate mofetil, and sirolimus, and 
no further intravenous immunoglobulin infusions were 
necessary. After treatment for polyradiculoneuropathy, the 
depigmented lesions did not improve or spread.
Chronic inflammatory demyelinating polyradiculo-
neuropathy may be associated with several autoimmune 
conditions. Furthermore, a previous study described a 
patient who had chronic inflammatory demyelinating 
polyradiculoneuropathy with melanoma and vitiligo 
[13]. However, the association of chronic inflammatory 
demyelinating polyradiculoneuropathy with vitiligo is 
rare.  Though the coexistence of these two diseases in the 
same patient could be merely coincidental, the proposed 
autoimmune nature of  both diseases might suggest a 
relationship between them. Melanocytes and Schwann cells 
are derived from the neural crest, share potential surface 
antigens including MAG [14] and gangliosides (GM2, GM3, 
GD3, GD2) [15] and thus may share common antigenic 
components with peripheral nerve.  Although we did not 
detect anti-MAG or anti-GM1 antibodies, the possibility of 
antibodies directed against a common antigen is intriguing 
and shared immunoreactivity may have accounted for the 
association between leukoderma and chronic inflammatory 
demyelinating polyradiculoneuropathy in our patient.
References
1. Filipovich AH, Weisdorf D, Pavletic S, et al. National 
Institutes of Health consensus development project on 
criteria for clinical trials in chronic graft-versus-host disease: 
I. Diagnosis and staging working group report. Biol Blood 
Marrow Transplant 2005;11:945-56.
2. Tran K, Kaplan J, Kamino H, Latkowski J-A. Graft-vs-host 
disease. Dermatol Online J 2013 ; 19: 20710.
3. Batırel A, Özer S, Gençer S,  et al. İmmunkompetan bir 
hastada ortopedik cerrahi sonrası gelişen transfüzyonla ilişkili 
graft versus host hastalığı. Marmara Med J 2006; 19:36-40. 
4. Hymes SR, Alousi AM, Cowen EW. Graft-versus-host 
disease: part I.   Pathogenesis and clinical manifestations of 
graft-versus-host disease. J Am Acad Dermatol 2012;66:515.
e1-e18.doi: 10.1016/j.jaad.2011.11.960
5. Shimada M, Onizuka M, Machida S, et al. Association 
of autoimmune disease-related gene polymorphisms with 
chronic graft-versus-host disease. Br J Haematol 2007; 139: 
458-63.  
6. Kang HY, Kang WH. Leukomelanoderma following acute 
cutaneous graft-versus-host disease. Eur J Dermatol 2004; 14: 
115Okan et al.
Leukoderma and polyradiculoneuropathyMarmara Medical Journal 2015; 28: 112-115
146–9.
7. Imamura M, Hashino S, Kobayashi H, et al. Serum cytokine 
levels in bone marrow transplantation: synergic interaction of 
interleukin-6, interferon-gamma and tumor necrosis factor-
alpha in graft versus-host disease. Bone Marrow Transplant 
1994; 13: 745-51.      
8. Tan AW, Koh LP, Goh BK. Leucoderma in chronic 
graft-versus-host disease: excellent repigmentation with 
noncultured cellular grafting.  Br J Dermatol 2011 ; 165: 435-
37. doi: 10.1111/j.1365-2133.2011.10341
9. Van den Bergh PY, Hadden RD, Bouche  P, et al. European 
Federation of Neurological Societies/Peripheral Nerve 
Society Guideline on management of chronic inflammatory 
demyelinating polyradiculoneuropathy: Report of a joint task 
force of the European Federation of Neurological Societies and 
the Peripheral Nerve Society - First Revision. Eur J  Neurol 
2010; 17: 356-63. doi: 10.1111/j.1468-1331.2009.02930
10. Lorenzoni PJ, Scola RH, Carsten AL, et al. Chronic 
inflammatory demyelinating polyradiculoneuropathy in 
chronic graft-versus-host disease following allogeneic 
hematopoietic stem cell transplantation: case report. Arq 
Neuropsiquiatr 2007 ;65:700-4.
11.  Doi Y, Sugahara H, Yamamoto K, et al. Immune-mediated 
peripheral neuropathy occurring simultaneously with recurrent 
graft-versus-host disease after allogenic hematopoietic stem 
cell transplantation. Leuk Res. 2012 ;36:e63-5. doi: 10.1016/j.
leukres.2011.11.025.Epub 2011 Dec 17.
12. Gorson KC. An update on the management of chronic 
inflammatory demyelinating polyneuropathy. Ther Adv 
Neurol Disord 2012; 5: 359-73.  
 doi: 10.1177/1756285612457215
13. Bird SJ, Brown MJ, Shy ME, et al. Chronic inflammatory 
demyelinating polyneuropathy associated with malignant 
melanoma. Neurology 1996 ; 46:822-4.
14. Noronha AB, Harper JR, Ilyas AA, et al. Myelin-associated 
glycoprotein shares an antigenic determinant with a 
glycoprotein of human melanoma cells. J Neurochem 1986 ; 
47:1558-65.
15. Tsuchida T, Saxton RE, Morton DL, et al. Gangliosides of 
human melanoma. Cancer 1989; 63:1166-74.
